These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 57019)

  • 1. Surface immunoglobulins of lymphocytes in mouse plasmacytoma. IV. Evidence for the persistence of the effect of plasmacytoma-RNA on the surface immunoglobulins of normal lymphocytes in vivo and in vitro.
    Bhoopalam N; Yakulis V; Giacomoni D; Heller P
    Clin Exp Immunol; 1976 Jan; 23(1):139-48. PubMed ID: 57019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface immunoglobulins of lymphocytes in plasmacytoma. V. The effect of RNA-rich extract from mouse plasmacytoma MOPC 104E on the immune response.
    Bhoopalam N; Chen Y; Yakulis V; Heller P
    Clin Exp Immunol; 1976 May; 24(2):357-67. PubMed ID: 1277583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of intracisternal A-particles and of RNA molecules in plasmacytoma-associated immunodeficiency.
    Katzmann J; Bhoopalam N; Heller P; Hwang LT; Ostro M; Lavelle D; Giacomoni D
    Cancer Res; 1978 Aug; 38(8):2555-61. PubMed ID: 307429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte surface membrane immunoglobulin in myeloma. I. M315-bearing T lymphocytes in mice with MOPC-315.
    Gebel HM; Hoover RG; Lynch RG
    J Immunol; 1979 Sep; 123(3):1110-6. PubMed ID: 313945
    [No Abstract]   [Full Text] [Related]  

  • 6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased T gamma and T mu cells in BALB/c mice with IgG and IgM plasmacytomas and hybridomas.
    Mathur A; Lynch RG
    J Immunol; 1986 Jan; 136(2):521-5. PubMed ID: 2934474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocompetence status as related to growth progression of mouse MOPC-315 plasmacytoma.
    Rashid G; Ophir R; Pecht M; Ben-Efraim S
    In Vivo; 1989; 3(4):279-84. PubMed ID: 2535271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoregulation of murine myeloma: isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo.
    Rohrer JW; Odermatt B; Lynch RG
    J Immunol; 1979 May; 122(5):2011-9. PubMed ID: 87450
    [No Abstract]   [Full Text] [Related]  

  • 12. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
    Mokyr MB; Barker E
    Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
    Wang KC; Berczi I; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
    Ghanta VK; Hiramoto NS; Hiramoto RN
    Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
    Shanahan TC; Ceglowski WS; Havas HF
    Cancer Res; 1985 Dec; 45(12 Pt 1):6463-70. PubMed ID: 2866030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific regulation of myeloma cell differentiation in vivo by carrier-specific T cell factors and macrophages.
    Rohrer JW; Lynch RG
    J Immunol; 1978 Sep; 121(3):1066-74. PubMed ID: 80422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mode of action of splenic suppressor cells in murine plasmacytoma.
    Chen Y; Heller P
    Clin Exp Immunol; 1981 Sep; 45(3):514-22. PubMed ID: 6461449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of BSF-1 during an in vivo, T-dependent immune response.
    Finkelman FD; Ohara J; Goroff DK; Smith J; Villacreses N; Mond JJ; Paul WE
    J Immunol; 1986 Nov; 137(9):2878-85. PubMed ID: 3489779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.